The Facilities for Illness Management and Prevention (CDC) vaccine advisory group in the present day really useful a second 2024-25 COVID-19 vaccine dose, spaced 6 months aside, for individuals ages 65 and older and for individuals in youthful age-groups who’ve average or extreme immunocompromising situations.
The group additionally really useful an additional dose, three or extra, in individuals with immunocompromising situations, primarily based on shared decision-making between affected person and physician.
The advice replaces a vaguer “further doses” wording that the Advisory Committee for Immunization Practices (ACIP) utilized in its recommendation over the summer season for at-risk teams for the 2024-25 vaccines. The group made the change to simplify and standardize language used for its routine immunization schedules.
The three-part vote handed unanimously.
Challenges in sustaining safety
The ACIP work group that proposed the advice grappled with a number of components, together with a scarcity of seasonality of SARS-CoV-2 circulation, the epidemiology of the illness, waning vaccine effectiveness, and variant adjustments.
Vaccine timing has turn into complicated, particularly given tough-to-predict waves involving new COVID variants that generally spike in warm-weather months, after safety from vaccination within the fall months has waned, however earlier than up to date vaccines arrive in the marketplace. For instance, over the previous spring and summer season, COVID exercise circulated at a excessive degree over many months.
Hospitalization charges from COVID stay larger in seniors, particularly these ages 75 and older.
Based on the CDC’s newest information for the final respiratory illness season, 40% of adults ages 65 and older obtained one dose of the vaccine and eight.9% obtained a second dose, with second-dose ranges larger in individuals in city areas and in sure geographic areas. CDC consultants instructed the group {that a} healthcare supplier suggestion helped sway sufferers to obtain a second dose.
In the meantime, second-dose protection in immunocompromised individuals ages 18 and older was decrease, at 5.4%.
Additional flexibility for immunocompromised teams
Additionally, together with the final two-dose suggestion for immunocompromised individuals ages 6 months to 64 years, in a transfer to create extra flexibility with COVID vaccination, ACIP really useful further doses—three or extra—of the 2024-25 vaccine in individuals ages 6 months and older who’re reasonably to severely immunocompromised with shared medical decision-making.
CDC consultants really useful a minimal 2-month vaccination interval to permit for flexibility primarily based on the affected person’s dangers and circumstances.
The CDC director considers ACIP suggestions earlier than making a proper suggestion.
